Pacira Biosciences Inc (PCRX) FinancialsPCRXPacira Biosciences Inc

Pacira BioSciences, Inc. (PCRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is EXPAREL, accounting for 77.6% of total sales, equivalent to $147.82M. Other significant revenue streams include ZILRETTA and iovera. Understanding this composition is critical for investors evaluating how PCRX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Pacira BioSciences, Inc. maintains a gross margin of 69.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.48%, while the net margin is 2.42%. These profitability ratios, combined with a Return on Equity (ROE) of 2.05%, provide a clear picture of how effectively PCRX converts its operational activities into shareholder value.

In the context of the broader market, PCRX competes directly with industry leaders such as LXRX and OBX. With a market capitalization of $1.03B, it holds a significant position in the sector. When comparing efficiency, PCRX's gross margin of 69.60% stands against LXRX's 94.36% and OBX's N/A. Such benchmarking helps identify whether Pacira BioSciences, Inc. is trading at a premium or discount relative to its financial performance.

Pacira has shown stable revenue growth with Q2 2026 total revenues reaching $192.4 million, reflecting a 6.2% increase year-over-year. The gross margin for Q2 was 69.60%, indicating strong profitability. The company has also improved its net income, reporting $4.65 million for Q2 2026, a positive sign for long-term investors.